+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Sage Therapeutics Inc (SAGE) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 70 Pages
  • May 2024
  • GlobalData
  • ID: 4278650
Sage Therapeutics Inc (SAGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers, develops and markets drugs for the treatment of central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors of NMDA and GABA. Its flagship product Zulresso (brexanolone) is a proprietary intravenous (IV) formulation administered for the treatment of postpartum depression (PPD). The company also has various pipeline products for the treatment of indications such as major depressive disorders, bipolar depression, Parkinson's disease, insomnia, epileptiform disorders, and NMDA hypofunction. The company operates in the US, Bermuda, Germany, Switzerland, Scotland, England, and Wales through its subsidiaries. Sage is headquartered in Cambridge, Massachusetts, the US.

Sage Therapeutics Inc Key Recent Developments

  • Apr 25, 2024: Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
  • Feb 14, 2024: Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
  • Jan 08, 2024: Sage Therapeutics Announces Changes to Board of Directors
  • Nov 07, 2023: Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Sage Therapeutics Inc - Key Facts
  • Sage Therapeutics Inc - Key Employees
  • Sage Therapeutics Inc - Key Employee Biographies
  • Sage Therapeutics Inc - Major Products and Services
  • Sage Therapeutics Inc - History
  • Sage Therapeutics Inc - Company Statement
  • Sage Therapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Sage Therapeutics Inc - Business Description
  • R&D Overview
  • Sage Therapeutics Inc - Corporate Strategy
  • Sage Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Sage Therapeutics Inc - Strengths
  • Sage Therapeutics Inc - Weaknesses
  • Sage Therapeutics Inc - Opportunities
  • Sage Therapeutics Inc - Threats
  • Sage Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Sage Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 25, 2024: Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
  • Feb 14, 2024: Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
  • Jan 08, 2024: Sage Therapeutics Announces Changes to Board of Directors
  • Nov 07, 2023: Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
  • Aug 07, 2023: Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights
  • May 02, 2023: Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
  • Mar 16, 2023: Sage Therapeutics Appoints Jessica Federer to Board of Directors
  • Feb 16, 2023: Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
  • Feb 02, 2023: Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
  • Jan 08, 2023: Sage Therapeutics to provide update on 2023 key initiatives at 41st Annual J.P. Morgan Healthcare Conference
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Sage Therapeutics Inc, Key Facts
  • Sage Therapeutics Inc, Key Employees
  • Sage Therapeutics Inc, Key Employee Biographies
  • Sage Therapeutics Inc, Major Products and Services
  • Sage Therapeutics Inc, History
  • Sage Therapeutics Inc, Subsidiaries
  • Sage Therapeutics Inc, Key Competitors
  • Sage Therapeutics Inc, Ratios based on current share price
  • Sage Therapeutics Inc, Annual Ratios
  • Sage Therapeutics Inc, Interim Ratios
  • Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Sage Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Sage Therapeutics Inc, Performance Chart (2019 - 2023)
  • Sage Therapeutics Inc, Ratio Charts
  • Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Supernus Pharmaceuticals Inc
  • Trevi Therapeutics Inc
  • Praxis Precision Medicines Inc
  • Cerevel Therapeutics Inc
  • Sumitomo Pharma America Inc
  • Marinus Pharmaceuticals Inc
  • Jazz Pharmaceuticals Plc
  • Amgen Inc
  • Applied Therapeutics Inc